← back to search

David Pearson

Novartis (Switzerland) · CH
Area of research
Oncology · Mechanics of Materials
Research interest
Research interests include Medicine, Internal medicine, Pembrolizumab, Oncology, Immunotherapy, and Cytokine release syndrome.
h-index
citations
87
works
3
NIH funding
primary concept
email

Recent publications

POS0046 PRELIMINARY RESULTS OF AN OPEN-LABEL, MULTICENTRE, PHASE 1/2 STUDY TO ASSESS SAFETY, EFFICACY AND CELLULAR KINETICS OF YTB323 (RAPCABTAGENE AUTOLEUCEL), A RAPIDLY MANUFACTURED CAR T-CELL THERAPY TARGETING CD19 ON B CELLS, FOR SEVERE REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
Annals of the Rheumatic Diseases 2024cited by 8position: middledoi
Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).
Journal of Clinical Oncology 2023cited by 37position: middledoi
Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results
Blood Advances 2022cited by 42position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Julia Weinmann‐Menke · German Society of Surgery1 papers (2024–2024)David S. Quinn · AbbVie (United States)1 papers (2023–2023)Clive Drakeford · Royal College of Surgeons in Ireland1 papers (2024–2024) · 1 papers (2022–2022)Adam S. Sperling · Harvard University1 papers (2023–2023) · 1 papers (2023–2023)T. Kirsilä · Novartis (Switzerland)1 papers (2024–2024) · 1 papers (2024–2024) · 1 papers (2024–2024)Yifang Li · Guangzhou University of Chinese Medicine1 papers (2023–2023)Serena De Vita · Harvard Stem Cell Institute1 papers (2023–2023)B Kovács · AbbVie (United States)1 papers (2024–2024)Yan Du · Sun Yat-sen University1 papers (2022–2022)Jessica Liegel · University of Minnesota, Twin Cities1 papers (2023–2023)Ulrich Jaeger · Comprehensive Cancer Center Vienna1 papers (2022–2022)Sarah Nikiforow · Harvard University1 papers (2023–2023)P Gergely · Novartis (Switzerland)1 papers (2024–2024)Isabelle Fleury · Hôpital Maisonneuve-Rosemont1 papers (2022–2022)Peter A. Riedell · Janssen (United States)1 papers (2022–2022)O. Fischer · Novartis (Switzerland)1 papers (2024–2024)